γ-氨基丁酸B受体在抑郁与奖赏中的作用
本文综述GABAB受体在抑郁、奖赏及二者交汇的快感缺失中的作用。GABAB受体表达与功能受抗抑郁药增强、在抑郁动物模型中降低;拮抗剂一般抗抑郁样、激动剂促抑郁样,例外与GABAB1亚型差异有关。GABAB受体参与尼古丁奖赏,激活减弱、失活增强奖赏及相关神经生物学改变;尼古丁戒断中激动剂、拮抗剂和正向别构调节剂均增强快感缺失。正向别构调节剂可分离激动剂的不良心副作用,即将进入药物滥用临床研究。
要点
- GABAB受体拮抗剂一般呈抗抑郁样作用,激动剂呈促抑郁样作用,例外与GABAB1亚型差异有关。
- GABAB受体激活减弱尼古丁奖赏,失活增强奖赏;尼古丁戒断中激动剂、拮抗剂和正向别构调节剂均增强快感缺失。
- 正向别构调节剂可分离激动剂的不良反应,即将进入药物滥用临床研究。
核心结论
- GABAB受体在抑郁、奖赏和快感缺失中起重要作用,GABAB1亚型是理解快感缺失神经生物学的关键。
- 正向别构调节剂可能提供靶向奖赏与抑郁相关特定脑区和过程的机制。
研究设计与样本
- 本文为综述,聚焦GABAB受体在抑郁、奖赏及快感缺失中的作用,并以致敬Athina Markou的生活与工作为主题。
主要发现
- GABAB受体表达和功能被抗抑郁药增强,在抑郁动物模型中降低。
- GABAB受体拮抗剂一般呈抗抑郁样作用,激动剂一般呈促抑郁样作用,例外可能反映GABAB1亚型对抑郁相关行为和神经生物学的差异影响,包括社会应激的快感缺失效应。
- GABAB受体激活减弱尼古丁奖赏及相关神经生物学改变,失活则增强这些效应。
- 在尼古丁戒断中,GABAB受体激动剂、拮抗剂和正向别构调节剂均增强快感缺失,可能归因于GABAB1亚型对多巴胺系统的差异效应。
- 尼古丁线索诱导的复吸更可靠地被GABAB受体激活所减弱。
临床怎么用
- 正向别构调节剂可分离激动剂的不良反应,即将进入药物滥用临床研究,提示其作为靶向GABAB受体治疗策略的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The metabotropic gamma-aminobutyric acid B (GABAB) receptor was the first described obligate G protein-coupled receptor heterodimer and continues to set the stage for discoveries in G protein-coupled receptor signaling complexity. In this review, dedicated to the life and work of Athina Markou, we explore the role of GABAB receptors in depression, reward, and the convergence of these domains in anhedonia, a shared symptom of major depressive disorder and withdrawal from drugs of abuse. GABAB receptor expression and function are enhanced by antidepressants and reduced in animal models of depression. Generally, GABAB receptor antagonists are antidepressant-like and agonists are pro-depressive. Exceptions to this rule likely reflect the differential influence of GABAB1 isoforms in depression-related behavior and neurobiology, including the anhedonic effects of social stress. A wealth of data implicate GABAB receptors in the rewarding effects of drugs of abuse. We focus on nicotine as an example. GABAB receptor activation attenuates, and deactivation enhances, nicotine reward and associated neurobiological changes. In nicotine withdrawal, however, GABAB receptor agonists, antagonists, and positive allosteric modulators enhance anhedonia, perhaps owing to differential effects of GABAB1 isoforms on the dopaminergic system. Nicotine cue-induced reinstatement is more reliably attenuated by GABAB receptor activation. Separation of desirable and undesirable side effects of agonists is achievable with positive allosteric modulators, which are poised to enter clinical studies for drug abuse. GABAB1 isoforms are key to understanding the neurobiology of anhedonia, whereas allosteric modulators may offer a mechanism for targeting specific brain regions and processes associated with reward and depression.
引用
- Jacobson LH, Vlachou S, Slattery DA, et al. The Gamma-Aminobutyric Acid B Receptor in Depression and Reward. Biol Psychiatry. 2018. PMID: 29759132. doi:10.1016/j.biopsych.2018.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。